Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

View Full Paper
Ask AI
Bookmark
Share

Authors

GFGeorg‐Nikolaus FrankeTHTobias A.W. HolderriedJVJurjen Versluis

Discussion

Loading...

Member takes

Overview

Registry analysis shows venetoclax with hypomethylating agents improves outcomes in relapsed AML post HSCT, indicating effectiveness of salvage therapies.

Key Points

  • This research examines the role of hypomethylating agents and venetoclax in treating relapsed acute myeloid leukemia after stem cell transplant.
  • Registry-based multicenter analysis of adults relapsing post HSCT
  • Comparative outcomes of HMA/VEN versus HMA alone
  • Evaluation of cumulative incidence of complete response (CR) and overall survival
  • 224 patients relapsed with a median of 181 days post HSCT
  • Higher 1-year cumulative incidence of CR in the HMA/VEN group at 44% versus 26%
  • Patients receiving HMA/VEN had a median time to CR of 62 days compared to 115 days for HMA alone

Cite This Study

Franke et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b2https://doi.org/10.1182/blood-2025-6079
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hypomethylating Agents-Venetoclax (HMA-VEN) as Salvage Therapy for Relapse of AML and MDS after Allogeneic HCT2026
  2. 2Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database2025
  3. 3Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience2024 · 12 citations
  4. 4Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)2025
  5. 5Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes2025